• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Perrigo Company plc

    5/5/26 5:20:10 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    S-8 POS 1 d49074ds8pos.htm S-8 POS S-8 POS

    As Filed with the Securities and Exchange Commission on May 5, 2026

    Registration Statement No. 333-234536

    Registration Statement No. 333-261074

    Registration Statement No. 333-270089

    Registration Statement No. 333-277416

    Registration Statement No. 333-287050

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-234536

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-261074

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270089

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277416

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-287050

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERRIGO COMPANY PLC

    (Exact name of registrant as specified in its charter)

     

     

     

    Ireland   Not Applicable

    (State or other jurisdiction

    of incorporation or organization)

     

    (IRS Employer

    Identification No.)

    The Sharp Building, Hogan Place

    Dublin 2, Ireland

    Telephone: +353 1 7094000

    (Address, including zip code, and telephone number, including

    area code, of registrant’s principal executive office)

    PERRIGO COMPANY PLC 2019 LONG-TERM INCENTIVE PLAN

    PERRIGO COMPANY PLC 2026 LONG-TERM INCENTIVE PLAN

    (Full Title of the Plans)

    Charles M. Atkinson

    Executive Vice President, General Counsel and Company Secretary

    Perrigo Company plc

    515 Eastern Avenue

    Allegan, Michigan 49010

    Telephone: (269) 686-1941

    (Name, address, including zip code, and telephone number,

    including area code, of agent for service)

    Copies to:

    Alan J. Fishman

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, New York 10004

    (212) 558-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filler   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    On April 30, 2026, the shareholders of Perrigo Company plc (the “Company” or the “Registrant”) approved the Perrigo Company plc 2026 Long-Term Incentive Plan (the “2026 Plan”). The total number of ordinary shares, nominal value €0.001 per share (“Ordinary Shares”), authorized for issuance under the 2026 Plan, subject to adjustment as provided in the 2026 Plan, is (i) 7,265,000 new Ordinary Shares, plus (ii) the number of Ordinary Shares underlying outstanding awards under the Perrigo Company plc 2019 Long-Term Incentive Plan (the “2019 Plan”) that are forfeited, terminated, expire unexercised or are otherwise settled without delivery of Ordinary Shares (1,004,649 of which, together with the Ordinary Shares under clause (i), are registered concurrently on a new registration statement on Form S-8), plus (iii) the number of Ordinary Shares that remain available for issuance under the 2019 Plan as of the effective date of the 2026 Plan, which is 1,463,572 Ordinary Shares (the Ordinary Shares under clause (iii), the “Prior Plan Shares”).

    In accordance with Item 512(a)(1)(iii) of Regulation S-K, this Post-Effective Amendment No. 1 to Registration Statement No. 333-234536, Post-Effective Amendment No. 1 to Registration Statement No. 333-261074, Post-Effective Amendment No. 1 to Registration Statement No. 333-270089, Post-Effective Amendment No. 1 to Registration Statement No. 333-277416 and Post-Effective Amendment No. 1 to Registration Statement No. 333-287050 (together, the “Post-Effective Amendments”) are hereby filed to register the issuance of the Prior Plan Shares pursuant to the 2026 Plan.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Items 1 and 2 of Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the respective participants in the plans covered by these Post-Effective Amendments and as required by Rule 428(b)(1).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The following documents filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

     

      (1)

    The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”);

     

      (2)

    The Company’s Current Reports on Form 8-K filed on March 23, 2026, April  30, 2026, and May 5, 2026;

     

      (3)

    The description of the Company’s Ordinary Shares, contained in Exhibit 4.17 to the Annual Report.

    All documents that the Company files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) subsequent to the effective date of these Post-Effective Amendments (except for any portions of the Company’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), but prior to the filing of a post-effective amendment to these Post-Effective Amendments indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in these Post-Effective Amendments and to be a part hereof from the date of filing such documents.

     

    1


    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of these Post-Effective Amendments to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of these Post-Effective Amendments.

    ITEM 4. DESCRIPTION OF SECURITIES.

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

    The Company’s articles of association confer an indemnity on its directors and secretary subject to the limitations prescribed by the Irish Companies Act 2014 (as amended) (the “Irish Companies Act”). Broadly, the relevant provisions in the Company’s articles of association provide for an indemnity for certain persons, including directors, the secretary, committee members, persons holding executive or official positions with the Company and employees, agents and persons acting in certain other capacities at the request of the Company (“Indemnified Persons”) who are a party to actions, suits or proceedings against expenses and costs in connection with such actions, suits or proceedings if such Indemnified Person acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to the best interests of the Company. Indemnification is also excluded in circumstances where an Indemnified Person is adjudged liable for willful neglect or default in performance of his duties unless a relevant court determines otherwise. Such indemnification may include expense advancement in certain circumstances.

    The Irish Companies Act prescribe that an advance commitment to indemnify only permits a company to pay the costs or discharge the liability of a director or secretary where judgment is given in favor of the director or secretary in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or secretary acted honestly and reasonably and ought fairly to be excused. Any provision whereby an Irish company seeks to commit in advance to indemnify its directors or secretary over and above the limitations imposed by the Irish Companies Act will be void, whether contained in its articles of association or any contract between the company and the director or secretary. This restriction does not apply to executives who are not directors or the secretary, or other persons who would not be considered “officers” within the meaning of that term under the Irish Companies Act, of the Company.

    Each of the Company’s current directors, officers and the secretary are party to individual indemnification agreements that provide for the indemnification of any claims relating to their services to the Company or any of its subsidiaries to the fullest extent permitted by applicable law.

    The Company also maintains directors’ and officers’ liability insurance and fiduciary liability insurance covering certain liabilities that may be incurred by its directors and officers in the performance of their duties.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

    Not applicable.

    ITEM 8. EXHIBITS.

    For the list of exhibits, see the Exhibit Index to these Post-Effective Amendments, which is incorporated in this item by reference.

     

    2


    ITEM 9. UNDERTAKINGS.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act ) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    3


    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Description of Exhibit

    4.1    Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed December 19, 2013) (File No. 333-192946)
    4.2    Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025) (File No. 001-36353)
    4.3    Perrigo Company plc 2026 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 5, 2026) (File No. 001-36353)
    4.4    Perrigo Company plc 2019 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 30, 2019) (File No. 001-36353).
    4.5    Amendment No.  1 to Perrigo Company plc 2019 Long Term Incentive Plan (incorporated by reference from Exhibit A to the Company’s Definitive Proxy Statement filed on March 24, 2022) (File No. 001-36353).
    4.6    Amendment No. 2 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated August  2, 2023 (incorporated by Reference from Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    4.7    Amendment No. 3 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated November  1, 2023 (incorporated by Reference from Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    5.1*    Opinion of A&L Goodbody
    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm for Perrigo Company plc
    23.2*    Consent of A&L Goodbody (included in Exhibit 5.1)
    24.1*    Powers of Attorney (included as part of the signature page hereto)
     
    *

    Filed herewith

     

    4


    SIGNATURES AND POWER OF ATTORNEY

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on May 5, 2026.

     

    PERRIGO COMPANY PLC
    By  

    /s/ Charles M. Atkinson

      Name:   Charles M. Atkinson
      Title:   Executive Vice President, General Counsel and Company Secretary

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Patrick Lockwood-Taylor, Eduardo Bezerra and Charles Atkinson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to these Post-Effective Amendments, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, these Post-Effective Amendments have been signed by the following persons in the capacities and on the date indicated on May 5, 2026.

     

    Signature    Title

    /s/ Patrick Lockwood-Taylor

       Chief Executive Officer and President (Principal Executive Officer) and Director
    Patrick Lockwood-Taylor   

    /s/ Eduardo Bezerra

       Chief Financial Officer and Executive Vice President (Principal Accounting and Financial Officer)
    Eduardo Bezerra   

    /s/ Bradley A. Alford

       Director
    Bradley A. Alford   

    /s/ Orlando D. Ashford

       Director
    Orlando D. Ashford   

    /s/ Julia M. Brown

       Director
    Julia M. Brown   

    /s/ Kevin Egan

       Director
    Kevin Egan   

    /s/ Albert A. Manzone

       Director
    Albert A. Manzone   

     

    5


    /s/ Donal O’Connor

       Director
    Donal O’Connor   

    /s/ Geoffrey M. Parker

       Director
    Geoffrey M. Parker   

    /s/ Jonas Samuelson

       Director
    Jonas Samuelson   

     

    6

    Get the next $PRGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    11/6/2025$20.00Overweight → Neutral
    Analyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. exercised 7,305 units of Ordinary Shares at a strike of $10.84 and covered exercise/tax liability with 3,507 units of Ordinary Shares, increasing direct ownership by 13% to 32,710 units (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    5/15/26 4:59:52 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Lockwood-Taylor Patrick

    4 - PERRIGO Co plc (0001585364) (Issuer)

    5/15/26 3:41:34 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP & Chief Financial Officer Bezerra Eduardo Guarita

    4 - PERRIGO Co plc (0001585364) (Issuer)

    5/15/26 3:38:50 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Analyst with a new price target

    Analyst downgraded Perrigo from Overweight to Neutral and set a new price target of $20.00

    11/6/25 8:47:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    SEC Form 144 filed by Perrigo Company plc

    144 - PERRIGO Co plc (0001585364) (Subject)

    5/28/26 2:43:06 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    5/7/26 11:04:28 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    5/7/26 10:31:04 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference

    DUBLIN, May 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on Tuesday, June 9th at 10:30 AM EDT.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About PerrigoPerrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing hi

    5/26/26 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

    Mitigating category headwinds with market share gains through implementation of Three‑S plan.Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed®, Opill®, and ellaOne® brands.Completed divestiture of Dermacosmetics business after quarter end; upfront proceeds of approximately €306 million will support debt reduction.Maintained full‑year 2026 outlook with continued expectation for second half improvement.DUBLIN, May 6, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quart

    5/6/26 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Completes Divestiture of Dermacosmetics Business

    Advances key Three-S plan pillar, streamlining portfolioUpfront net proceeds of approximately €306 million will enable debt reductionDUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next th

    4/30/26 4:30:00 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

    Mitigating category headwinds with market share gains through implementation of Three‑S plan.Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed®, Opill®, and ellaOne® brands.Completed divestiture of Dermacosmetics business after quarter end; upfront proceeds of approximately €306 million will support debt reduction.Maintained full‑year 2026 outlook with continued expectation for second half improvement.DUBLIN, May 6, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quart

    5/6/26 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, April 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pionee

    4/29/26 8:56:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026

    DUBLIN, April 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that it plans to issue its first quarter 2026 financial results on Wednesday, May 6, 2026, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 82404. A taped replay of the call will be available b

    4/22/26 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care